These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23448382)

  • 1. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France.
    Bruley des Varannes S; Löfman HG; Karlsson M; Wahlqvist P; Ruth M; Furstnau ML; Despiégel N; Stålhammar NO
    BMC Gastroenterol; 2013 Feb; 13():39. PubMed ID: 23448382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.
    Toghanian S; Johnson DA; Stålhammar NO; Zerbib F
    Clin Drug Investig; 2011 Oct; 31(10):703-15. PubMed ID: 21756007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA.
    Stålhammar NO; Spiegel BM; Granstedt Löfman H; Karlsson M; Wahlqvist P; Næsdal J; Nelson MT; Despiégel N
    Pragmat Obs Res; 2012; 3():57-67. PubMed ID: 27774018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
    Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
    Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany.
    Gross M; Beckenbauer U; Burkowitz J; Walther H; Brueggenjuergen B
    Eur J Med Res; 2010 Mar; 15(3):124-30. PubMed ID: 20452898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of on-demand vs continuous prescription of proton pump inhibitors on symptom burden and quality of life: results of a real-world randomized controlled trial in primary care patients with gastroesophageal reflux disease.
    Andreasson A; Agréus L; Mastellos N; Bliźniuk G; Waśko-Czopnik D; Angelaki A; Theodosaki E; Lionis C; Hek K; Verheij R; Wright E; Durbaba S; Muris J; Bródka P; Saganowski S; Ethiér JF; Curcin V; Delaney B
    Ann Med; 2024 Dec; 56(1):2354683. PubMed ID: 38753973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
    Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
    Gosselin A; Luo R; Lohoues H; Toy E; Lewis B; Crawley J; Duh MS
    Value Health; 2009; 12(1):34-9. PubMed ID: 19895371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease.
    Rodríguez L; Rodriguez P; Gómez B; Ayala JC; Oxenberg D; Perez-Castilla A; Netto MG; Soffer E; Boscardin WJ; Crowell MD
    Surgery; 2015 Mar; 157(3):556-67. PubMed ID: 25726315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.
    Isshi K; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Ogawa M; Arihiro S; Haruma K; Nakada K
    J Gastroenterol; 2019 Jun; 54(6):492-500. PubMed ID: 30673836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction?].
    Labenz J; Labenz G; Stephan D; Willeke F;
    MMW Fortschr Med; 2016 May; 158 Suppl 4():7-11. PubMed ID: 27221555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population.
    Doan QV; Lange SM; Elfant A; Aguilar D; Reyes E; Lynn RB; Dubois RW
    J Med Econ; 2008; 11(1):23-40. PubMed ID: 19450108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations.
    Vakil N; Niklasson A; Denison H; Rydén A
    BMC Gastroenterol; 2014 Oct; 14():177. PubMed ID: 25304129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Sci Rep; 2020 Jan; 10(1):769. PubMed ID: 31964957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study.
    Rydén A; Martin M; Halling K; Niklasson A
    Patient; 2013; 6(4):307-14. PubMed ID: 23990378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
    Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort.
    Wahlqvist P; Karlsson M; Johnson D; Carlsson J; Bolge SC; Wallander MA
    Aliment Pharmacol Ther; 2008 May; 27(10):960-70. PubMed ID: 18315585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater loss of productivity among Japanese workers with gastro-esophageal reflux disease (GERD) symptoms that persist vs resolve on medical therapy.
    Suzuki H; Matsuzaki J; Masaoka T; Inadomi JM
    Neurogastroenterol Motil; 2014 Jun; 26(6):764-71. PubMed ID: 24602100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.